APO-LAMOTRIGINE 25 MG
LAMOTRIGINE : 25 MG · DIN 02245208 · APOTEX INC
Health Canada status: MARKETED
What is APO-LAMOTRIGINE?
APO-LAMOTRIGINE 25 MG contains LAMOTRIGINE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02245208, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Mar-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is APO-LAMOTRIGINE called?
The same molecule, LAMOTRIGINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Lamictal | Latin | Australia, Czechia, Morocco, Saudi Arabia |
| Lamotrigine GH | Latin | Australia |
| Sandoz Lamotrigine | Latin | Australia |
| SYNNAX | Latin | Morocco |
| APX-Lamotrigine | Latin | Australia |
| LAMITAN | Latin | Australia |
| LAMOTRIGINE-WGR | Latin | Australia |
| Logem | Latin | Australia |
| LAMOTRIX | Latin | Czechia |
| Arrow Lamotrigine | Latin | South Africa |
| Aspen Lamotrigine | Latin | South Africa |
| Lameptil | Latin | South Africa |
| LAMICTAL LIQUI-TABS | Latin | Bahrain |
| LAMOTRIGIN ACTAVIS | Latin | Czechia |
| Lamotrigine QO | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02245208 |
|---|---|
| Brand name | APO-LAMOTRIGINE |
| Generic / active ingredient | LAMOTRIGINE : 25 MG |
| Manufacturer | APOTEX INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX09 LAMOTRIGINE |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Mar-2002 |
| Original market date | 2002-03-18 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02245208 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245208 |
| Brand name | APO-LAMOTRIGINE |
| Active ingredient / INN | LAMOTRIGINE : 25 MG |
| ATC code | N03AX09 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03 |
| AHFS class | 28:12.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is LAMOTRIGINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N03AX09 LAMOTRIGINE. 29 of 48 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-LAMOTRIGINE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543729 |
| AG-LAMOTRIGINE | 150 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543737 |
| AG-LAMOTRIGINE | 25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543710 |
| APO-LAMOTRIGINE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02245209 |
| APO-LAMOTRIGINE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02245210 |
| AURO-LAMOTRIGINE | 100 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381362 |
| AURO-LAMOTRIGINE | 150 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381370 |
| AURO-LAMOTRIGINE | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381354 |
| JAMP LAMOTRIGINE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02542749 |
| JAMP LAMOTRIGINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02542757 |
Who else supplies LAMOTRIGINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LAMOTRIGINE appears in 882 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LAMOTRIGINE cost around the world?
LAMOTRIGINE is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 11 | 92 | AUD███.██ |
| United States | acquisition | 6 | 88 | USD███.██ |
| South Africa | single exit price | 59 | 80 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 6 | 33 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 30 | 30 | EUR███.██ |
| Saudi Arabia | public | 14 | 24 | SAR███.██ |
| Morocco | PPV (public price) | 2 | 22 | MAD███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Luxembourg | reimbursement | 16 | 16 | EUR███.██ |
| United Arab Emirates | public | 12 | 12 | AED███.██ |
| Bahrain | retail (max) | 3 | 10 | BHD███.██ |
425 pack listings across 177 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every LAMOTRIGINE pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.